Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Abstract Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA approved for treatment of HNSCC. Takin...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Bottomly, Chase Mathieson, Myles Vigoda, Sophia Jeng, Nathaniel Evans, Ashley Anderson, Aurora Blucher, Aletha Lesch, Christina Zheng, Ted Laderas, James Jacobs, Molly Kulesz-Martin, Shannon McWeeney
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Scientific Reports
Subjects:
HNSCC
Antitumor drug screening assays
Multi-Omics
Online Access:https://doi.org/10.1038/s41598-025-03111-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-03111-7

Similar Items